Scholarlink

Background <p>Painful distal symmetric polyneuropathy (DSPN) is one of the most common complications of type 2 diabetes mellitus (T2DM), affecting quality of life and increasing the disease burden. Standard pharmacological treatments often provide suboptimal relief and may cause adverse effects, highlighting the need for alternative therapies. Electroacupuncture (EA), a traditional Chinese medicine technique, has shown promising clinical outcomes in pain reduction, but its role in diabetic neuropathy remains underexplored. This pilot clinical trial aimed to assess the efficacy of EA in reducing neuropathic pain in patients with T2DM and axonal DSPN.</p> Methods <p>We conducted a pilot randomized, double-blind, sham-controlled trial in northern Mexico City (December 2021—August 2023). Eighteen patients with clinically and electrophysiologically confirmed axonal DSPN were randomly assigned to receive either true EA or sham EA, twice weekly for eight weeks (16 sessions, 20&#xa0;min each). Neuropathic pain was evaluated using the Douleur Neuropathique en 4 Questions (DN-4) and Numeric Rating Scale (NRS) at baseline and post-intervention.</p> Findings <p>After 16 sessions, the median DN-4 score change was not significant in either group. In contrast, the NRS scores showed reductions in the EA group: -2.78 points for current pain intensity (-58% from baseline, <i>p</i> = 0.028), -2.11 for least pain (-40%, <i>p</i> = 0.028), -4 for worst pain (-19%, <i>p</i> = 0.050), and -3.67 for average pain (-63%, <i>p</i> &lt; 0.001). No significant changes were observed in the sham EA group. No adverse effects were reported.</p> Conclusion <p>This pilot randomized clinical trial suggests that EA may reduce pain intensity compared to sham EA in patients with painful DSPN. However, these findings should be regarded as hypothesis-generating given the limited sample size. Larger, multicentre trials are needed to confirm these results and explore underlying mechanisms.</p> Trial registration <p>CNIC-IMSS (R-2020–785-070; registered prospectively on May 26th, 2020), CONBIOÉTICA (09CEI00920160601), COFEPRIS (CI: 17 CI 09 015 006), ClinicalTrials.gov (NCT05521737; retrospectively registered on August 30th, 2022; first participant enrolled December 2021), and the International Clinical Trials Registry platform (ISRCTN97391213, retrospectively registered on September 12th, 2022).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of electroacupuncture for pain relief in diabetic distal symmetric polyneuropathy: a pilot randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • María Fernanda Pérez Hernández,
  • Eduardo Rodríguez Guerrero,
  • María Esther Ocharan Hernández,
  • Daniel Cuauhtémoc Gómez Jiménez,
  • Mónica Luz Gómez Esquivel,
  • Sergio de Jesús Aguilar Castillo,
  • Vera Denisse Flores Hernández,
  • Sofia Romo Dueñas,
  • Mario Rafael Torres Mendoza,
  • Alejandra Calderón Vallejo,
  • Germán Velázquez García,
  • Macedonia Guadalupe Moreno Tovar,
  • Miguel Cruz López,
  • Juan Manuel Ordóñez Rodríguez,
  • Karla Aridahí Peña Juárez,
  • Ximena Miranda Gastelum,
  • José María Castro Díaz,
  • Alejandra Aguirre Guerrero,
  • Víctor Manuel Macías Zaragoza,
  • José de Jesús Peralta Romero

摘要

Background

Painful distal symmetric polyneuropathy (DSPN) is one of the most common complications of type 2 diabetes mellitus (T2DM), affecting quality of life and increasing the disease burden. Standard pharmacological treatments often provide suboptimal relief and may cause adverse effects, highlighting the need for alternative therapies. Electroacupuncture (EA), a traditional Chinese medicine technique, has shown promising clinical outcomes in pain reduction, but its role in diabetic neuropathy remains underexplored. This pilot clinical trial aimed to assess the efficacy of EA in reducing neuropathic pain in patients with T2DM and axonal DSPN.

Methods

We conducted a pilot randomized, double-blind, sham-controlled trial in northern Mexico City (December 2021—August 2023). Eighteen patients with clinically and electrophysiologically confirmed axonal DSPN were randomly assigned to receive either true EA or sham EA, twice weekly for eight weeks (16 sessions, 20 min each). Neuropathic pain was evaluated using the Douleur Neuropathique en 4 Questions (DN-4) and Numeric Rating Scale (NRS) at baseline and post-intervention.

Findings

After 16 sessions, the median DN-4 score change was not significant in either group. In contrast, the NRS scores showed reductions in the EA group: -2.78 points for current pain intensity (-58% from baseline, p = 0.028), -2.11 for least pain (-40%, p = 0.028), -4 for worst pain (-19%, p = 0.050), and -3.67 for average pain (-63%, p < 0.001). No significant changes were observed in the sham EA group. No adverse effects were reported.

Conclusion

This pilot randomized clinical trial suggests that EA may reduce pain intensity compared to sham EA in patients with painful DSPN. However, these findings should be regarded as hypothesis-generating given the limited sample size. Larger, multicentre trials are needed to confirm these results and explore underlying mechanisms.

Trial registration

CNIC-IMSS (R-2020–785-070; registered prospectively on May 26th, 2020), CONBIOÉTICA (09CEI00920160601), COFEPRIS (CI: 17 CI 09 015 006), ClinicalTrials.gov (NCT05521737; retrospectively registered on August 30th, 2022; first participant enrolled December 2021), and the International Clinical Trials Registry platform (ISRCTN97391213, retrospectively registered on September 12th, 2022).